Serum Metabolic Profiles of the Tryptophan-Kynurenine Pathway in the high risk subjects of major depressive disorder

Chronic unpredictable mild stress-induced behavioral changes are coupled with dopaminergic hyperfunction and serotonergic hypofunction in mouse models of depression

(2019) Qiaohui Lu et al.   BEHAVIOURAL BRAIN RESEARCH

Kynurenine pathway in depression: A systematic review and meta-analysis

(2018) Kamiyu Ogyu et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Alterations in the metabolism of tryptophan in patients with chronic hepatitis C six months after pegylated interferon-α 2a treatment

(2018) Tomasz Pawlowski et al.   PSYCHONEUROENDOCRINOLOGY

Alterations in serum kynurenine pathway metabolites in individuals with high neocortical amyloid-β load: A pilot study

(2018) Pratishtha Chatterjee et al.   Scientific Reports

Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder

(2018) Yanling Zhou et al.   PSYCHONEUROENDOCRINOLOGY

L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences

(2017) Hidetsugu Fujigaki et al.   NEUROPHARMACOLOGY

Depressive symptoms as a side effect of Interferon-α therapy induced by induction of indoleamine 2,3-dioxygenase 1

(2016) Yuki Murakami et al.   Scientific Reports

Inflammation and increased IDO in hippocampus contribute to depression-like behavior induced by estrogen deficiency

(2015) Yongjun Xu et al.   BEHAVIOURAL BRAIN RESEARCH

Pain and depression comorbidity: A preclinical perspective

(2015) Jun-Xu Li   BEHAVIOURAL BRAIN RESEARCH

Neuroplasticity Underlying the Comorbidity of Pain and Depression

(2015) Lisa Doan et al.   NEURAL PLASTICITY

Does tryptophan degradation along the kynurenine pathway mediate the association between pro-inflammatory immune activity and depressive symptoms?

(2014) Jacqueline Quak et al.   PSYCHONEUROENDOCRINOLOGY

Serotonin – Kynurenine Hypothesis of Depression: Historical Overview and Recent Developments

(2013) Gregory Oxenkrug   CURRENT DRUG TARGETS

Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder

(2013) Daimei Sasayama et al.   JOURNAL OF PSYCHIATRIC RESEARCH

The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1 and with increased CSF KYNA level and reduced KMO expression

(2013) C Lavebratt et al.   MOLECULAR PSYCHIATRY

Kynurenines: from the perspective of major psychiatric disorders

(2012) Aye M. Myint   FEBS Journal

MAGE-D1 Regulates Expression of Depression-Like Behavior through Serotonin Transporter Ubiquitylation

(2012) A. Mouri et al.   JOURNAL OF NEUROSCIENCE

Immune changes and neurotransmitters: Possible interactions in depression?

(2012) Barbara Sperner-Unterweger et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Indoleamine 2,3 dioxygenase and metabolic control of immune responses

(2012) David H. Munn et al.   TRENDS IN IMMUNOLOGY

Immune modulation of learning, memory, neural plasticity and neurogenesis

(2010) Raz Yirmiya et al.   BRAIN BEHAVIOR AND IMMUNITY

Increased Levels of Kynurenine and Kynurenic Acid in the CSF of Patients With Schizophrenia

(2010) K. R. Linderholm et al.   SCHIZOPHRENIA BULLETIN

Dispositional optimism and stress-induced changes in immunity and negative mood

(2009) Lena Brydon et al.   BRAIN BEHAVIOR AND IMMUNITY

Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice

(2008) J C O'Connor et al.   MOLECULAR PSYCHIATRY